For some, mild headaches may come and go during dose changes or as their eating habits evolve
For the treatment-regimen estimand, the mean body weight reductions from baseline at 72 weeks were 15.0%, 19.5%, and 20.9% in the tirzepatide 5, 10, and 15 mg groups, respectively, versus 3.1% in the placebo group
[51] World Health Organization
GLP-1 receptor agonists are generally well-tolerated, but clinicians and patients must understand their adverse effect profile, particularly when considering use in individuals with eating disorders who may have unique vulnerabilities
Myo-inositol is the form of inositol to seek, and thats what Life Extension provides in its third-party-tested product, and its easy to titrate your dose upward